DE69534118T2 - Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene - Google Patents

Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene Download PDF

Info

Publication number
DE69534118T2
DE69534118T2 DE69534118T DE69534118T DE69534118T2 DE 69534118 T2 DE69534118 T2 DE 69534118T2 DE 69534118 T DE69534118 T DE 69534118T DE 69534118 T DE69534118 T DE 69534118T DE 69534118 T2 DE69534118 T2 DE 69534118T2
Authority
DE
Germany
Prior art keywords
headache
migraine
inhibitor
antagonist
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69534118T
Other languages
German (de)
English (en)
Other versions
DE69534118D1 (de
Inventor
Jes Olesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69534118D1 publication Critical patent/DE69534118D1/de
Publication of DE69534118T2 publication Critical patent/DE69534118T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DE69534118T 1994-05-11 1995-05-10 Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene Expired - Fee Related DE69534118T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94610027 1994-05-11
EP94610027 1994-05-11
PCT/IB1995/000415 WO1995031195A1 (en) 1994-05-11 1995-05-10 Use of no scavengers, inhibitors or antagonists in the treatment of migraine

Publications (2)

Publication Number Publication Date
DE69534118D1 DE69534118D1 (de) 2005-05-04
DE69534118T2 true DE69534118T2 (de) 2006-02-09

Family

ID=8218183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534118T Expired - Fee Related DE69534118T2 (de) 1994-05-11 1995-05-10 Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene

Country Status (12)

Country Link
US (1) US6265441B1 (enExample)
EP (1) EP0758890B1 (enExample)
JP (2) JPH10500129A (enExample)
AT (1) ATE291909T1 (enExample)
AU (1) AU704059B2 (enExample)
CA (1) CA2189762C (enExample)
DE (1) DE69534118T2 (enExample)
DK (1) DK0758890T3 (enExample)
ES (1) ES2238074T3 (enExample)
PT (1) PT758890E (enExample)
SI (1) SI0758890T1 (enExample)
WO (1) WO1995031195A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270531C (en) * 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
AU1824300A (en) * 1998-11-23 2000-06-13 Linden Biotechnology, Inc. Combination products of a guanylate cyclase inhibitor and a local anesthetic forpain relief
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
US20080274206A1 (en) * 2004-10-07 2008-11-06 Ngen Pharmaceuticals N.V. Stabilised Oxygen Releasing Composition
WO2007009462A2 (en) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
US20090191283A1 (en) * 2008-01-24 2009-07-30 Oronsky Bryan Todd Treatment of headaches, neck pain, joint pain and inflammatory-type pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
FR2707494B1 (fr) 1993-07-02 1995-08-25 Roussel Uclaf Nouvelle utilisation de dérivés de la béta-naphtoquinone ainsi que de leurs sels.
SK16396A3 (en) * 1993-08-12 1996-09-04 Astra Ab Amidine derivatives with nitric oxide synthetase activities
GB9317686D0 (en) 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
EP0759027B1 (en) * 1994-05-07 1999-08-04 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase

Also Published As

Publication number Publication date
EP0758890A1 (en) 1997-02-26
DK0758890T3 (da) 2005-04-18
US6265441B1 (en) 2001-07-24
AU704059B2 (en) 1999-04-15
SI0758890T1 (enExample) 2005-08-31
JPH10500129A (ja) 1998-01-06
CA2189762A1 (en) 1995-11-23
CA2189762C (en) 2009-01-13
JP2007137906A (ja) 2007-06-07
AU2417995A (en) 1995-12-05
ES2238074T3 (es) 2005-08-16
EP0758890B1 (en) 2005-03-30
DE69534118D1 (de) 2005-05-04
PT758890E (pt) 2005-06-30
ATE291909T1 (de) 2005-04-15
WO1995031195A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
DE69333874T2 (de) Verwendung von vier K-252a Derivaten
DE69728782T2 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
DE69930552T2 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
DE69113938T2 (de) Zusammensetzungen von Maillard-Reaktion inhibitoren.
DE60202278T2 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
DE69022678T2 (de) S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.
EP0607775B1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
DE3505359A1 (de) Arzneimittel zur behandlung von akuter, myocardialer ischaemie
DE69425820T2 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE4410997A1 (de) Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
DE69534118T2 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
EP0038438B1 (de) Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel
DE60002226T2 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
DE69508551T2 (de) Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
DE69330842T2 (de) Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration
EP0035597A2 (de) Pharmazeutische Zubereitungen
DE3234537C2 (de) Verwendung von 3-(2,2,2-Trimethylhydrazinium)propionatdihydrat zur Behandlung kardiovaskulärer Erkrankungen
DE69430047T2 (de) Pharmazeutische Zusammensetzungen die Isochinolinderivate enthalten
CH647677A5 (de) 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung.
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE69123580T2 (de) Verwendung von antagonisten des plättchen-aktivierenden faktors bei pruritus
EP0223850B1 (de) Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten
DE2528460A1 (de) Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE2749520A1 (de) Harnstoffderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische und veterinaermedizinische zusammensetzungen
DE69123573T2 (de) Synergistische zusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee